FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote

FDA approves AstraZeneca's camizestrant for breast cancer despite negative advisory committee vote

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) in combination with CDK4/6 inhibitors for ESR1-mutated breast cancer, overriding a negative advisory committee recommendation.